BioCentury
ARTICLE | Product Development

Axsome speeds Alzheimer's agitation trial, citing patient vulnerability and FDA guidance

March 20, 2020 2:48 PM GMT
Updated on Mar 20, 2020 at 9:05 PM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Axsome Therapeutics Inc.

Next in Daily Edition for March 20, 2020